Disease Landscape and Forecast Insights

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the United States and Europe. The majority of patients with advanced AMD have the wet form of the…

Schizophrenia is a chronic and disabling psychiatric condition that affects approximately 1.8 million Americans. Patients with schizophrenia can present with a range of symptoms that are…

With no significant drug launches occurring in more than a decade, the overarching treatment paradigms in Alzheimer’s disease (AD) are mostly stable. However, understanding what factors and…

The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral (ARV) agents, particularly the latest single-tablet regimens (STRs), which offer improved safety and…

Emerging Therapies: Nucala (US) is a three-wave syndicated detailed expanded analysis that specifically tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic…

The U.S. rheumatoid arthritis (RA) market is crowded, with the availability of nine different biologics and Xeljanz, representing six distinct drug classes. With the impending entry of biosimilars…

An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS…

Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza—are approved in the United States for metastatic colorectal cancer. Therefore, medical…

Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma in China and South Korea. The prevalence of this chronic disease remains high owing to the…

Acromegaly is a chronic endocrine disorder characterized by hypersecretion of growth hormone and overproduction of insulin-like growth factor-1. Nearly all cases of acromegaly are caused by an…

In the last ten years, TNF-α inhibitors have transformed the treatment of axial spondyloarthritis, including ankylosing spondylitis and nonradiographic axial spondyloarthritis, and have brought…

Due to rising antibiotic resistance rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs),…